UNSPSC 51342500: Antiviral nucleosides

Antiviral drugs made from purine or pyrimidine bases attached to a ribose or deoxyribose.

UNSPSC 51342500 Antiviral nucleosides is a Class code, but the recent state and local opportunities tagged under it show minimal alignment with the code's nominal scope. The four most recent solicitations demonstrate a mismatch: Seminole County, Florida is procuring naloxone and drug deactivation systems; the City of Tampa is seeking medical and first aid supplies for fire rescue operations; Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic multi-source pharmaceuticals and OTC products. Of these, only the Texas HHS RFI and MMCAP RFP touch on pharmaceutical procurement broadly, but neither targets antivirals specifically. The naloxone and Tampa medical supplies solicitations address emergency response and community health but fall outside antiviral scope. The code shows little relevant recent activity for antiviral nucleosides procurement at the state and local level.

The geographic spread of the four tagged opportunities spans Florida, Texas, Minnesota, and Oregon, reflecting a national footprint across state health agencies, counties, cities, and cooperative purchasing entities. Issuing bodies include a county health department (Seminole County), a city fire department (Tampa), a state health commission (Texas HHS), and a multistate purchasing cooperative (MMCAP). Representative recent activity includes Seminole County IFB 60459723LAS for naloxone and safe drug deactivation systems with a July 26, 2023 response deadline; the City of Tampa's ITB 26P00145 for medical and first aid supplies for fire rescue with a March 13, 2026 deadline and an estimated contract value of $700,000; Texas HHS RFI HHS0017013 for direct-to-manufacturer prescription capabilities with an April 3, 2026 response date; and MMCAP RFP S1070000015802 for generic pharmaceuticals and OTC products with a March 26, 2026 proposal deadline. None of these solicitations target antivirals as a primary procurement category.